Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tenax TherapeuticsTENX +8.99%22 3-Year EBITDA Growth Rate is 87.00% as of Jun. 2026, which is 98% above its 10-year median of 43.90. GuruFocus rates TENX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,127 Biotechnology companies, Tenax Therapeutics ranks better than 97.52% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 87.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 82.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 61.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Tenax Therapeutics was 92.30% per year. The lowest was 10.20% per year. And the median was 43.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Tenax Therapeutics 3-Year EBITDA Growth Rate Related Terms
TENX vs MAIA, TELO, CING: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Tenax Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenax Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Tenax Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 87.00% mean?
Tenax Therapeutics (TENX) has a 3-Year EBITDA Growth Rate of 87.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Tenax Therapeutics and its competitors. This is 98% above median its historical median of 43.90. Over the past decade, Tenax Therapeutics' 3-Year EBITDA Growth Rate has ranged from 10.20 to 92.30. According to the industry distribution chart, Tenax Therapeutics ranks #28 out of 1127 companies in the Biotechnology industry, placing it in the top 2.5%.
Is Tenax Therapeutics' 3-Year EBITDA Growth Rate too high?
Tenax Therapeutics' current 3-Year EBITDA Growth Rate of 87.00% is 98% above median its 10-year median of 43.90. Over the past 10 years, this metric has ranged from a low of 10.20 to a high of 92.30. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Tenax Therapeutics' value of 87.00% is 495.9% above this industry median. Based on the distribution chart, Tenax Therapeutics ranks #28 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tenax Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Tenax Therapeutics' 3-Year EBITDA Growth Rate compare to MAIA and TELO?
According to the Biotechnology industry distribution chart, Tenax Therapeutics ranks #28 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Tenax Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.60. Tenax Therapeutics' value of 87.00% is 495.9% above this benchmark. Historically, Tenax Therapeutics' own 3-Year EBITDA Growth Rate has ranged from 10.20 to 92.30 over the past decade. While the company's 10-year median is 43.90 vs. the industry median of 14.60, Tenax Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tenax Therapeutics's current 3-Year EBITDA Growth Rate of 87.00% is 495.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Tenax Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tenax Therapeutics's current 3-Year EBITDA Growth Rate is 87.00%, which is 98% above median its own 10-year median of 43.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenax Therapeutics stock overvalued right now?
Tenax Therapeutics (TENX) has a current 3-Year EBITDA Growth Rate of 87.00%. The current 3-Year EBITDA Growth Rate is 87.00%, which is 98% above median its 10-year median of 43.90 and 495.9% above the Biotechnology industry median of 14.60. Tenax Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Tenax Therapeutics (TENX), the current 3-Year EBITDA Growth Rate is 87.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
22GF Score
Get the complete analysis for TENX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TENX has been successfully added to your 
